United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fintel reports that on April 21, 2025, B of A Securities upgraded their outlook for United Therapeutics (NasdaqGS:UTHR) from ...

As previously reported, BofA analyst Jason Gerberry upgraded United Therapeutics (UTHR) to Neutral from Underperform with an unchanged price ...

BofA upgraded United Therapeutics (UTHR) to Neutral from Underperform with a $314 price target Stay Ahead of the Market: Discover ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Nasdaq 100, S&P 500, Dow Jones Industrial Average, Barrick Gold Corp. Read 's Market Analysis on Investing.com ...

Have you been searching for a stock that might be well-positioned to maintain its earnings-beat streak in its upcoming report? It is worth considering United Therapeutics (UTHR), which belongs to the ...

It is worth considering United Therapeutics (UTHR), which belongs to the Zacks Medical - Drugs industry. This drugmaker has an established record of topping earnings estimates, especially when ...

However, once they added the PH-ILD indication, UTHR filed a lawsuit again. On what basis? As LQDA management noted: ...we are disappointed that United Therapeutics has elected to file this ...

Get the next trade alert free. Beam Therapeutics Inc. BEAM on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD ...